The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis: The BAT Randomized Controlled Trial
Abstract
IMPORTANCE: Macrolide antibiotics have been shown beneficial in cystic fibrosis (CF) and diffuse panbronchiolitis, and earlier findings also suggest a benefit in non-CF bronchiectasis. OBJECTIVE: To determine the efficacy of macrolide maintenance treatment for adults with non-CF bronchiectasis. DESIGN, SETTING, AND PARTICIPANTS: The BAT (Bronchiectasis and Long-term Azithromycin Treatment) study, a randomized, double-blind, placebo-controlled trial conducted between April 2008 and September 2010 in 14 hospitals in The Netherlands among 83 outpatients with non-CF bronchiectasis and 3 or more lower respiratory tract infections in the preceding year. INTERVENTIONS: Azithromycin (250 mg daily) or placebo for 12 months. MAIN OUTCOME MEASURES: Number of infectious exacerbations during 12 months of treatment. Secondary end points included lung function, sputum bacteriology, inflammatory markers, adverse effects, symptom scores, and quality of life. RESULTS: Forty-three participants (52%) received azithromycin and 40 (48%) received placebo and were included in the modified intention-to-treat analysis. At end of study, the median number of exacerbations in the azithromycin group was 0 (interquartile range [IQR], 0-1), compared with 2 (IQR, 1-3) in the placebo group (P < .001). Thirty-two (80%) placebo-treated vs 20 (46%) azithromycin-treated individuals had at least 1 exacerbation (hazard ratio, 0.29 [95% CI, 0.16-0.51]). In a mixed-model analysis, change in forced expiratory volume in the first second of expiration (percent of predicted) over time differed between groups (F1,78.8 = 4.085, P = .047), with an increase of 1.03% per 3 months in the azithromycin group and a decrease of 0.10% per 3 months in the placebo group. Gastrointestinal adverse effects occurred in 40% of patients in the azithromycin group and in 5% in the placebo group (relative risk, 7.44 [95% CI, 0.97-56.88] for abdominal pain and 8.36 [95% CI, 1.10-63.15] for diarrhea) but without need for discontinuation of study treatment. A macrolide resistance rate of 88% was noted in azithromycin-treated individuals, compared with 26% in the placebo group. CONCLUSIONS AND RELEVANCE: Among adults with non-CF bronchiectasis, the daily use of azithromycin for 12 months compared with placebo resulted in a lower rate of infectious exacerbations. This could result in better quality of life and might influence survival, although effects on antibiotic resistance need to be considered. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00415350.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035
Azithromycin for prevention of exacerbations of COPD
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104623 · Cited by 1,226
Saiman, L., Marshall, B. C., Mayer-Hamblett, N., Burns, J. L., Quittner, A. L., Cibene, D. A., Coquillette, S., Fieberg, A. Y., Accurso, F. J., Campbell III, P. W., et al. (2003) · JAMA · doi:10.1001/jama.290.13.1749 · Cited by 958
Azithromycin and the Risk of Cardiovascular Death
Ray, W. A., Murray, K. T., Hall, K., Arbogast, P. G., & Stein, C. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1003833 · Cited by 954
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Wong, C., Jayaram, L., Karalus, N., Eaton, T., Tong, C., Hockey, H., Milne, D., Fergusson, W., Tuffery, C., Sexton, P., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60953-2 · Cited by 600
Inflammation: a two-edged sword--the model of bronchiectasis.
Pj, C. (1986) · PubMed · Cited by 571
Equi, A., Balfour-Lynn, I., Bush, A., & Rosenthal, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11081-6 · Cited by 543
Wolter, J. (2002) · Thorax · doi:10.1136/thorax.57.3.212 · Cited by 518
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.10.006 · Cited by 414
Mortality in bronchiectasis: a long-term study assessing the factors influencing survival
Loebinger, M. R., Wells, A. U., Hansell, D. M., Chinyanganya, N., Devaraj, A., Meister, M., & Wilson, R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00003709 · Cited by 414
Validation of the St. George's Respiratory Questionnaire in Bronchiectasis
WILSON, C. B., JONES, P. W., O'LEARY, C. J., COLE, P. J., & WILSON, R. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.2.9607083 · Cited by 387
Snijders, D., Daniels, J. M. A., de Graaff, C. S., van der Werf, T. S., & Boersma, W. G. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200905-0808oc · Cited by 295
Self-citationClement, A. (2006) · Thorax · doi:10.1136/thx.2005.057950 · Cited by 292
Quality-of-Life Determinants in Patients With Clinically Stable Bronchiectasis
Martínez-García, M. A., Perpiñá-Tordera, M., Román-Sánchez, P., & Soler-Cataluña, J. J. (2005) · Chest · doi:10.1378/chest.128.2.739 · Cited by 208
A pilot study of low-dose erythromycin in bronchiectasis
Tsang, K., Ho, P., Chan, K., Ip, M., Lam, W., Ho, C., Yuen, K., Ooi, G., Amitani, R., & Tanaka, E. (1999) · European Respiratory Journal · doi:10.1183/09031936.99.13236199 · Cited by 197
Koh, Y., Lee, M., Sun, Y., Sung, K., & Chae, J. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10050994 · Cited by 141
Tramper‐Stranders, G. A., Wolfs, T. F. W., Fleer, A., Kimpen, J. L. L., & van der Ent, C. K. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000247109.44249.ac · Cited by 110
Yalçın, E., Ki̇per, N., Özçelik, U., Doğru, D., Fırat, P., Sahin, A., Ariyurek, M. O., Mocan, G., Gürcan, N., & Göçmen, A. (2006) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2006.00708.x · Cited by 108
Phaff, S. J., Tiddens, H. A. W. M., Verbrugh, H. A., & Ott, A. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl014 · Cited by 102
Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis
Anwar, G. A., Bourke, S. C., Afolabi, G., Middleton, P. G., Ward, C., & Rutherford, R. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.06.005 · Cited by 95
The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD
Banerjee, D., Khair, O. A., & Honeybourne, D. (2004) · Respiratory Medicine · doi:10.1016/j.rmed.2004.06.009 · Cited by 93
Altenburg, J., de Graaff, C. S., van der Werf, T. S., & Boersma, W. G. (2010) · Respiration · doi:10.1159/000320320 · Cited by 81
Self-citationUpdate on non-cystic fibrosis bronchiectasis
Bilton, D. (2008) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328312ed8c · Cited by 76
Knottnerus, J. A., & Bouter, L. M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00276-6 · Cited by 64
Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations
Serisier, D. J., & Martin, M. L. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.01.009 · Cited by 55
Dailyversusweekly azithromycin in cystic fibrosis patients
McCormack, J. G., Bell, S. C., Senini, S., Walmsley, K., Patel, K., Wainwright, C. E., Serisier, D. J., Harris, M., & Bowler, S. (2007) · European Respiratory Journal · doi:10.1183/09031936.00163306 · Cited by 55
Hansen, C. R., Pressler, T., Høiby, N., & Johansen, H. K. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.001 · Cited by 50
Cited by
European Respiratory Society guidelines for the management of adult bronchiectasis
Polverino, E., Goeminne, P. C., McDonnell, M. J., Aliberti, S., Marshall, S. E., Loebinger, M. R., Murris, M., Cantón, R., Torres, A., Dimakou, K., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00629-2017 · Cited by 1,333
The bronchiectasis severity index. An international derivation and validation study
Chalmers, J. D., Goeminne, P., Aliberti, S., McDonnell, M. J., Lonni, S., Davidson, J., Poppelwell, L., Salih, W., Pesci, A., Dupont, L. J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1575oc · Cited by 1,093
“Macrolide use is associated with a significant increase in adverse events, with 40% of macrolide-treated patients experiencing gastrointestinal side effects in the BAT trial (11).”
BackgroundInternational Consensus Document (ICON): Common Variable Immunodeficiency Disorders
Bonilla, F. A., Barlan, I., Chapel, H., Costa-Carvalho, B. T., Cunningham-Rundles, C., de la Morena, M. T., Espinosa-Rosales, F. J., Hammarström, L., Nonoyama, S., Quinti, I., et al. (2016) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2015.07.025 · Cited by 872
Azithromycin: Mechanisms of action and their relevance for clinical applications
Parnham, M. J., Haber, V. E., Giamarellos-Bourboulis, E. J., Perletti, G., Verleden, G. M., & Vos, R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.003 · Cited by 661
British Thoracic Society Guideline for bronchiectasis in adults
T Hill, A., L Sullivan, A., D Chalmers, J., De Soyza, A., Stuart Elborn, J., Andres Floto, R., Grillo, L., Gruffydd-Jones, K., Harvey, A., S Haworth, C., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212463 · Cited by 617
Metadata
- Authors
- Altenburg, J., de Graaff, C. S., Stienstra, Y., Sloos, J. H., van Haren, E. H. J., Koppers, R. J. H., van der Werf, T. S., & Boersma, W. G.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-03-27
- Volume
- 309
- Issue
- 12
- Pages
- 1251
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2108506420
- Cited by
- 518
- References
- 32
- FWCI
- 41.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.